Related Experiment Videos
[In vivo effect of etoposide on the function of bone marrow-derived macrophages]
M Nakanishi1, S Sone, N Inamura
1Third Dept. of Internal Medicine, University of Tokushima School of Medicine.
Abstract:
Proliferative and colony-forming abilities of bone marrow cells to M-CSF and the function of the bone marrow-derived macrophages were examined 2, 7, 14 and 21 days after intraperitoneal injection of etoposide. Only two days after administration of etoposide (50 mg/kg of body weight), the number of bone marrow cells per femur was significantly decreased, but completely recovered by day 7. In contrast, proliferative and colony-forming responses of the bone marrow cells to M-CSF was increased after 2 days, but there-after returned to the normal. The abilities of bone marrow-derived macrophages to adhere to plastics and to produce monokines (IL-1 and TNF) were the same as those of controls before and after treatment with etoposide. These data suggest that activation of macrophage progenitors in bone marrow may be useful in combination with chemotherapy for treatment of malignant diseases.
Insights
Etoposide temporarily reduces bone marrow cells but enhances their response to M-CSF. Macrophage function remains normal, suggesting potential combination therapy for cancers.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Context:
- Investigating the effects of etoposide, a chemotherapy agent, on bone marrow cellularity and function.
- Assessing the impact of etoposide on macrophage progenitor cells and their response to macrophage colony-stimulating factor (M-CSF).
Purpose:
- To evaluate the short-term effects of etoposide on bone marrow cell recovery and progenitor cell responsiveness.
- To determine the functional capacity of bone marrow-derived macrophages following etoposide treatment.
Summary:
- Etoposide administration (50 mg/kg) initially decreased bone marrow cellularity, with full recovery by day 7.
- Bone marrow cell proliferation and colony formation in response to M-CSF increased at day 2 post-etoposide but normalized thereafter.
- Bone marrow-derived macrophage adherence and monokine (IL-1, TNF) production were unaffected by etoposide treatment.
Impact:
- Suggests that enhancing macrophage progenitor activation in bone marrow could be a beneficial strategy when combined with etoposide chemotherapy.
- Highlights the potential for novel therapeutic approaches in treating malignant diseases by modulating bone marrow's immune response.